• 1
    Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 2000; 28: 11971205.
  • 2
    Hows JM, Bradley BA, Marsh JC, et al. Growth of human umbilical-cord blood in longterm haemopoietic cultures. Lancet 1992; 340: 7376.
  • 3
    Noort WA, Falkenberg JHF. Haematopoietic content of cord blood. In: CohenSB, GluckmanE, RubensteinP et al., eds. Cord Blood Characteristics: Role in Stem Cell Transplantation. London: Martin Dunitz, 2000:1337.
  • 4
    Bender JG, To LB, Williams S, et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329341.
  • 5
    Schwella N, Beyer J, Schwaner I, et al. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 1996; 14: 11141121.
  • 6
    Mavroudis D, Read E, Cottler-Fox M, et al. CD34+ cell dose predicts survival, post-transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 32233229.
  • 7
    Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3: 13371345.
  • 8
    Osawa M, Hanada K, Hamada H, et al. Long-term lympho-hematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996; 273: 242245.
  • 9
    Wang J, Kimura T, Asada R, et al. SCID-repopulating cell activity of human cord blood-derived CD34– cells assured by intra-bone marrow injection. Blood 2003; 101: 29242931.
  • 10
    Gallacher L, Murdoch B,Wu DM, et al. Isolation and characterization of human CD34(−)Lin(−) and CD34(+)Lin(−) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood 2000; 95: 28132820.
  • 11
    de Wynter EA, Buck D, Hart C, et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long- term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells 1998; 16: 387396.
  • 12
    Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 50025012.
  • 13
    Lathja LG. Stem cell concepts. Differentiation 1979; 14: 2334.
  • 14
    Fleming WH,Alpern EJ, Uchida N, et al. Functional heterogeneity is associated with the cell cycle status of murine hematopoietic stem cells. J Cell Biol 1993; 122: 897902.
  • 15
    Uchida N, He D, Friera AM, et al. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. Blood 1997; 89: 465472.
  • 16
    Yamaguchi M, Ikebuchi K, Hirayama F, et al. Different adhesive characteristics and VLA-4 expression of CD34(+) progenitors in G0/G1 versus S+G2/M phases of the cell cycle. Blood 1998; 92: 842848.
  • 17
    Shapiro HM. Flow cytometric estimation of DNA and RNA content in intact cells stained with Hoechst 33342 and pyroninY. Cytometry 1981; 2: 143150.
  • 18
    Leemhuis T,Yoder MC, Grigsby S, et al. Isolation of primitive human bone marrow hematopoietic progenitor cells using Hoechst 33342 and Rhodamine 123. Exp Hematol 1996; 24: 12151224.
  • 19
    Koller MR, Emerson EG, Palsson BO. Large-scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion cultures. Blood 1993; 82: 378384.
  • 20
    Koller MR, Oxender M, Brott DA, et al. Flt-3 ligand is more potent than c-kit ligand for the synergistic stimulation of ex vivo hematopoietic cell expansion. J Hematother 1996; 5: 449459.
  • 21
    Kohler T, Plettig R, Wetzstein W, et al. Defining optimum conditions for the ex vivo expansion of human umbilical cord blood cells: influences of progenitor enrichment, interference with feeder layers, early-acting cytokines and agitation of culture vessels. Stem Cells 1999; 17: 1924.
  • 22
    Gilmore GL, DePasquale DK, Lister J, et al. Ex vivo expansion of umbilical cord blood and peripheral blood CD34+ hematopoietic stem cells. Exp Haematol 2000; 28: 12971305.
  • 23
    McNiece I, Jones R, Bearman S, et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood 2000; 96: 30013007.
  • 24
    Zandstra PW, Conneally E, Piret JM, et al. Ontogeny-associated changes in the cytokine responses of primitive human haemopoietic cells. Br J Haematol 1998; 101: 770778.
  • 25
    Piacibello W, Sanavio F, Garetto L, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997; 89: 26442653.
  • 26
    Summers YJ, Heyworth CM, de Wynter EA, et al. Cord blood G0 CD34+ cells have a thousand fold higher capacity for generating progenitors in vitro than G1 CD34+ cells. Stem Cells 2001; 19: 505513.
  • 27
    de Wynter EA, Ryder D, Lanza F, et al. Multicentre European study comparing selection techniques for the isolation of CD34+ cells. Bone Marrow Transplant 1999; 23: 11911196.
  • 28
    Gothot A, Pyatt R, McMahel J, et al. Functional heterogeneity of human CD34+ cells isolated in subcompartments of the G0/G1 phase of the cell cycle. Blood 1997; 90: 43844393.
  • 29
    Piacibello W, Sanavio F, Severino A, et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34+ cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood 1999; 93: 37363749.
  • 30
    Testa NG, Molineux G. Haemopoiesis: A Practical Approach, Volume 1, First Edition. Oxford: Oxford University Press, 1993.
  • 31
    Sutherland HJ, Eaves CJ, Lansdorp PM, et al. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 1991; 78: 666672.
  • 32
    Pettengell R, Luft T, Henschler R, et al. Direct comparison by limiting dilution analysis of long-term culture-initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 1994; 84: 36533659.
  • 33
    Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies, I: data analysis. J Immunol 1981; 126: 16141619.
  • 34
    Miraglia S, Godfrey W, Yin AH, et al. A novel five-trans-membrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 50135021.
  • 35
    Buhring HJ, Seiffert M, Marxer A, et al. AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. Blood 1999; 94: 832833.
  • 36
    Vavrova J, Filip S, Vokurkova D, et al. Ex vivo expansion CD34+/AC133+-selected autologous peripheral blood progenitor cells (PBPC) in high-risk breast cancer patients receiving intensive chemotherapy. Hematol Cell Ther 1999; 41: 105112.
  • 37
    Matsumoto K,Yasui K,Yamashita N, et al. In vitro proliferation potential of AC133 positive cells in peripheral blood. Stem Cells 2000; 18: 196203.
  • 38
    Filip S, Vavrova J, Vokurkova D, et al. Myeloid differentiation and maturation of SCF+IL-3+IL-11 expanded AC133+/ CD34+ cells selected from high-risk breast cancer patients. Neoplasma 2000; 47: 7380.
  • 39
    Majka M, Ratajczak J, Machalinski B, et al. Expression, regulation and function of AC133, a putative cell surface marker of primitive human haematopoietic cells. Folia Histochem Cytobiol 2000; 38: 5363.
  • 40
    Pasino M, Lanza T, Marotta F, et al. Flow cytometric and functional characterization of AC133+ cells from human umbilical cord blood. Br J Haematol 2000; 108: 793800.
  • 41
    Kim DK, Fujiki Y, Fukushima T, et al. Comparison of hematopoietic activities of human bone marrow and umbilical cord blood CD34 positive and negative cells. Stem Cells 1999; 17: 286294.
  • 42
    Sato T, Laver JH, Ogawa M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood 1999; 94: 25482554.
  • 43
    Dao MA, Arevalo J, Nolta JA. Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood 2003; 101: 112118.
  • 44
    Gothot A, van der Loo JC, Clapp DW, et al. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34+ cells in non-obese diabetic/severe combined immune-deficient mice. Blood 1998; 92: 26412649.
  • 45
    Wilpshaar J, Falkenburg JHF, Tong X, et al. Similar repopulating capacity of mitotically active and resting umbilical cord blood CD34+ cells in NOD/SCID mice. Blood 2000; 96: 21002107.
  • 46
    Testa NG, de Wynter EA, Weaver A. The study of haemopoietic stem cells in patients: concepts, approaches and cautionary tales. Ann Oncol 1996; 7: 58.
  • 47
    Gan OI, Murdoch B, Larochelle A, et al. Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells. Blood 1997; 90: 641650.
  • 48
    Bhatia M, Bonnet D, Kapp U, et al. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture. J Exp Med 1997; 186: 619624.
  • 49
    Conneally E, Cashman J, Petzer A, et al. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lymphomyeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci U S A 1997; 94: 98369841.
  • 50
    Szilvassy SJ, Bass MJ, Van Zant G, et al. Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by ex vivo expansion. Blood 1999; 93: 15571566.